Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Tetsumori Yamashima
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer’s disease
10.1186/s13195-020-00680-9 · 2020
Addition of lysophospholipids with large head groups to cells inhibits Shiga toxin binding
10.1038/srep30336 · 2016
From zero to six double bonds: phospholipid unsaturation and organelle function
10.1016/j.tcb.2015.03.004 · 2015
Two pathways for lysophosphatidic acid production
10.1016/j.bbalip.2008.06.005 · 2008
Quantitative analysis of lysophosphatidic acid in human blood fractions
10.1111/j.1749-6632.2000.tb06557.x · 2000
Polyunsaturated fatty acids and their metabolites in brain function and disease
10.1038/nrn3820 · 2014
Inherited metabolic disease
1991
Organization and evolution of brain lipidome revealed by large-scale analysis of human, chimpanzee, macaque, and mouse tissues
10.1016/j.neuron.2015.01.003 · 2015
1-Oleoyl lysophosphatidic acid: a new mediator of emotional behavior in rats
10.1371/journal.pone.0085348 · 2014
Regulation of brain polyunsaturated fatty acid uptake and turnover
10.1016/j.plefa.2008.09.003 · 2008
Danger-sensing/patten recognition receptors and neuroinflammation in Alzheimer’s disease
10.3390/ijms21239036 · 2020
Lysophospholipids and their receptors in the central nervous system
10.1016/j.bbalip.2012.07.015 · 2013
The heterotrimeric G protein G alpha i2 mediates lysophosphatidic acid-stimulated induction of the c-fos gene in mouse fibroblasts
10.1074/jbc.272.2.773 · 1997
Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes
10.1186/1742-2094-11-37 · 2014
Essential role of phosphoinositide metabolism in synaptic vesicle recycling
10.1016/s0092-8674(00)81649-9 · 1999
The role of lysophosphatidic acid in neuropsychiatric and neurodegenerative disorders
10.3390/futurepharmacol4010014 · 2024
Lipidomics joins the omics evolution
10.1073/pnas.0812636106 · 2009
Phospholipase A2 enzymes: physical structure. Biological function, disease implications, chemical inhibition, and therapeutic intervention
10.1021/cr200085w · 2011
Phosphoinositides in cell regulation and membrane dynamics
10.1038/nature05185 · 2006
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
10.1038/nm.4050 · 2016
Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly
10.1177/1073858405285923 · 2006
Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders
10.1124/pr.58.3.7 · 2006
Emerging roles for lysophosphatidylserine in resolution of inflammation
10.1016/j.plipres.2012.03.001 · 2012
Biological effects of lysophosphatidic acid in the nervous system
10.1016/b978-0-12-394307-1.00005-9 · 2012
Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies
10.1038/s41392-020-00367-5 · 2021
Lysophosphatidic acid levels in cerebrospinal fluid and plasma samples in patients with major depressive disorder
10.1016/j.heliyon.2019.e01699 · 2019
From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin–plasmalogens derivates in Alzheimer’s disease human post mortem brains and mice model via mass spectrometry
10.1016/j.chroma.2011.07.073 · 2011
Phospholipase A2 – nexus of aging, oxidative stress, neuronal excitability, and functional decline of the aging nervous system? Insights from a snail model system of neuronal aging and age-associated memory impairment
10.3389/fgene.2014.00419 · 2014
Pleotropic roles of autotaxin in the nervous system present opportunities for the development of novel therapeutics for neurological diseases
10.1007/s12035-019-01719-1 · 2020
Amyloid-β peptide induces temporal membrane biphasic changes in astrocytes through cytosolic phospholipase A2
10.1016/j.bbamem.2008.07.027 · 2008
Dynamics of choline-containing phospholipids in traumatic brain injury and associated comorbidities
10.3390/ijms222111313 · 2021
Phospholipase D: a lipid centric review
10.1007/s00018-005-5195-z · 2005
The preservation of ultrastructure in saturated phosphatidyl cholines by tannic acid in model systems and type II pneumocytes
10.1083/jcb.74.3.726 · 1977
Novel trimodal MALDI imaging mass spectrometry (IMS3) at 10 mum reveals spatial lipid and peptide correlates implicated in Aβ plaque pathology in Alzheimer’s disease
10.1021/acschemneuro.7b00314 · 2017
LPA(1)-induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells
10.1002/jcp.22631 · 2011
The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer’s disease and mild cognitive impairment
10.1016/j.dadm.2015.05.003 · 2015
Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists
10.1038/sj.onc.1204187 · 2001
Metabolism of glycerolipides: a comparison of lecithin and triglyc-eride synthesis
10.1016/s0021-9258(18)70453-5 · 1958
Membrane lipids in presynaptic function and disease
10.1016/j.neuron.2016.02.033 · 2016
An updated review of lysophosphatidylcholine metabolism in human diseases
10.3390/ijms20051149 · 2019
An imbalanced ratio between PC(16:0/16:0) and LPC(16:0) revealed by lipidomics supports the role of the Lands cycle in ischemic brain injury
10.1074/jbc.ra120.016565 · doi-reference
Critical role for glycosphingolipids in Niemann-Pick disease type C
10.1016/s0960-9822(01)00396-7 · doi-reference
Eicosanoids derived from arachidonic acid and their family prostaglandins and cyclooxygenase in psychiatric disorders
10.2174/1570159x13666151102103305 · doi-reference
LPA signaling is required for dopaminergic neuron development and is reduced through low expression of the LPA1 receptor in a 6-OHDA lesion model of Parkinson’s disease
10.1007/s10072-015-2295-x · doi-reference
Cleavage of Hsp70.1 causes lysosomal cell death under stress conditions
10.3389/fmolb.2024.1378656 · doi-reference
Hsp70.1 carbonylation induces lysosomal cell death for lifestyle-related diseases
10.3389/fmolb.2022.1063632 · doi-reference
Vegetable oil-peroxidation product ‘hydroxynonenal’ causes hepatocyte injury and steatosis via Hsp70.1 and BHMT disorders in the monkey liver
10.3390/nu15081904 · doi-reference
Implication of the cooking oil-peroxidation product “hydroxynonenal” for Alzheimer’s disease
10.3389/fnagi.2023.1211141 · doi-reference
Intake of ω-6 polyunsaturated fatty acid-rich vegetable oils and risk of lifestyle diseases
10.1093/advances/nmaa072 · doi-reference
Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074: a novel strategy for neuroprotection based on ’calpain-cathepsin (hypothesis)
10.1046/j.1460-9568.1998.00184.x · doi-reference
Histological, ultrastructural and chromatographical discrimination of phospholipids in meningiomas
10.1007/bf00294642 · doi-reference
Implication of vegetable oil-derived hydroxynonenal in the lysosomal cell death for lifestyle-related diseases
10.3390/nu15030609 · doi-reference
Implication of cysteine proteases calpain, cathepsin and caspase in ischemic neuronal death of primates
10.1016/s0301-0082(00)00006-x · doi-reference
10.1016/b978-044453219-0.50013-1
10.1016/b978-044453219-0.50013-1 · doi-reference
Biological membranes
10.1042/bse0590043 · doi-reference
Changes in cognitive function, synaptic structure and protein expression after long-term exposure to 2.856 and 9.375 GHz microwaves
10.1186/s12964-022-01011-1 · doi-reference
Lipid imbalance in the neurological disorder, Niemann-Pick C disease
10.1016/j.febslet.2006.06.008 · doi-reference
Lysophosphatidic acid-induced neurite retraction in PC12 cells: control by phosphoinositide-Ca2+ signaling and Rho
10.1046/j.1471-4159.1996.66020537.x · doi-reference
Molecular anatomy of a trafficking organelle
10.1016/j.cell.2006.10.030 · doi-reference
Protein carbonylation
10.1089/ars.2009.2887 · doi-reference
Role of cytosolic phospholipase A2 in oxidative and inflammatory signaling pathways in different cell types in the central nervous system
10.1007/s12035-014-8662-4 · doi-reference
Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases
10.1194/jlr.r300016-jlr200 · doi-reference
Generation of membrane diversity by lysophospholipid acyltransferases
10.1093/jb/mvt048 · doi-reference
Lysophosphatidylcholine increases the neurotoxicity of Alzheimer’s amyloid β1-42 peptide: role of oligomer formation
10.1016/j.neuroscience.2015.02.034 · doi-reference
Formation of multilamellar vesicles by addition of tannic acid to phosphatidylcholine-containing small unilamellar veicles
10.1177/37.11.2809174 · doi-reference
GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction
10.1091/mbc.e05-07-0688 · doi-reference
Regulation of neuronal cytoskeleton by lysophosphatidic acid: role of GSK-3
10.1016/s1388-1981(02)00149-x · doi-reference
The neurite retraction induced by lysophosphatidic acid increases Alzheimer’s disease-like Tau phosphorylation
10.1074/jbc.274.52.37046 · doi-reference
The significance of plasma lysophospholipids in patients with renal failure on hemodialysis
10.3177/jnsv.44.809 · doi-reference
Relevance of multilamellar and multicompartmental vesicles in biological fluids: understanding the significance of proportional variations and disease correlation
10.1186/s40364-023-00518-0 · doi-reference
Ceramidase regulates synaptic vesicle exocytosis and trafficking
10.1523/jneurosci.1146-04.2004 · doi-reference
Neurochemical changes in LPA1 receptor deficient mice--a putative model of schizophrenia
10.1007/s11064-005-2611-6 · doi-reference
Evaluation of serum lysophosphatidic acid and lysophosphatidylcholine levels in major depressive disorder patients
10.7759/cureus.12388 · doi-reference
Lysophosphatidylcholine: potential target for the treatment of chronic pain
10.3390/ijms23158274 · doi-reference
Reduced Na+-K+-ATPase activity and plasma lysophosphatidylcholine concentrations in diabetic patients
10.2337/diab.43.7.915 · doi-reference
Effects of lysophosphatidylcholine on β-amyloid-induced neuronal apoptosis
10.1038/aps.2009.25 · doi-reference
Autotaxin: structure-function and signaling
10.1194/jlr.r046391 · doi-reference
Fear extinction and acute stress reactivity reveal a role of LPA receptor in regulating emotional-like behaviors
10.1007/s00429-013-0592-9 · doi-reference
Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease
10.1016/s0092-8674(05)80010-8 · doi-reference
Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine (lysoPC) in ovarian cancer patients
10.1002/(sici)1097-0215(19970328)71:1<31::aid-ijc7>3.0.co;2-4 · doi-reference